Superworth

ANI Pharmaceuticals price to book ratio ANIP

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
2.8×
10-year median
3.1×
Against its 10-year history
37th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.3× to 5.1×
Peer median
2.9×

ANI Pharmaceuticals' price to book ratio is 2.8× as of Oct 23, 2026.

That is below its ten-year median of 3.1×, close to the middle of its last ten years.

Over that time it ranged from 1.3× in Jun 2022 to 5.1× in Aug 2019.

The median for 10 large drugmakers of a similar size is 2.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.8×2.7×3.8×
20253.7×2.9×4.9×
20242.8×2.6×3.4×
20232.6×2.1×3.2×
20222.3×1.3×2.9×
20213.1×1.8×3.4×
20201.8×1.5×3.7×
20193.5×3.0×5.1×
20182.7×2.5×4.7×
20174.1×2.9×4.8×
20164.2×2.1×4.9×
20153.3×3.1×7.8×
20146.2×3.2×8.2×
20135.1×0.9×5.1×
20120.9×0.8×2.3×
20111.2×1.1×26.2×

Against its peers

Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ANIPANI Pharmaceuticals2.8×
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
HRMYHarmony Biosciences2.1×
PBHPrestige Consumer Healthcare1.2×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.4×
NRIXNurix Therapeutics2.9×
ABUSArbutus Biopharma3.2×
OGNOrganon3.6×
Peer median2.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on ANI Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.